Heart failure in patients with recently diagnosed atrial fibrillation: findings from the GLORIA-AF Registry Phase III.

Aims: Congestive heart failure (CHF) is often coexisting in patients with atrial fibrillation (AF), but the clinical epidemiology of this association is still uncertain. We aimed to analyse characteristics, management, and outcomes of patients with and without CHF, in a real-world cohort of patients with AF.

Methods And Results: From the GLORIA-AF Registry Phase III, which enrolled adults with a recent diagnosis of AF and a CHA2DS2-VASc ≥ 1, we analysed factors associated with CHF at baseline, the association of CHF with use of oral anticoagulants (OAC) and other treatments, and the risk of adverse outcomes during a 3-year follow-up.

History of falls in patients with atrial fibrillation and risk of major outcomes: analysis from the Prospective GLORIA-AF Registry.

Falls pose concerns for the management and prognosis of patients with atrial fibrillation (AF). Epidemiological data on patients with AF who fall are limited. From the prospective global GLORIA-AF Registry Phase III study, we evaluated patients with a recent diagnosis of AF and CHADS-VASc score ≥ 1 according to previous history of falling at baseline.

Physical activity in patients with atrial fibrillation and adverse outcomes: results from a large-scale prospective multicenter European cohort.

Introduction And Objectives: Increased physical activity may improve outcomes in patients with atrial fibrillation (AF), but available data are limited. This study aimed to analyze the association between physical activity and major adverse outcomes in a large European AF cohort.

Methods: We used data from a prospective, observational, large-scale multicenter study of AF in European patients, involving 27 countries and 250 centers.

Atrial fibrillation and female sex: use of oral anticoagulants in a large European cohort and residual risk of thromboembolism and stroke.

Background: The role of female sex in stroke risk and oral anticoagulant (OAC) use in atrial fibrillation (AF) remains controversial. This study evaluates sex-specific differences in OAC prescription, residual risk of stroke/TIA and thromboembolism (STE), and the predictive performance of CHA₂DS₂-VASc vs. CHA₂DS₂-VA scores.

Atrial fibrillation progression in patients with device-detected subclinical atrial fibrillation: Insights from the ARTESiA trial.

Background: The Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Subclinical Atrial Fibrillation (ARTESiA) trial enrolled patients with subclinical atrial fibrillation (SCAF) lasting < 24 hours.

Objective And Methods: We assessed the association of SCAF progression to clinical atrial fibrillation or SCAF > 24 hours with adverse outcomes and predictors of SCAF progression.

Results: During follow-up (4.

Distinct Platelet Phenotype and Reactivity in Individuals with Permanent Atrial Fibrillation Treated with Direct Oral Anticoagulants: A Pilot Study.

Atrial fibrillation (AF) is linked to an elevated risk of thromboembolic events. Despite the use of guideline-recommended direct anticoagulants (DOACs), a significant proportion of AF patients show a residual risk of thromboembolic events, driven by mechanisms that are not fully understood.We conducted a pilot study to characterize the platelet function in DOACs-treated AF patients, to explore whether an association between platelets and the residual thromboembolic risk exists.

Adherence to the ABC (atrial fibrillation better care) pathway and risk of adverse outcomes in patients with chronic kidney disease: a report from the prospective APHRS-AF registry.

Background: Limited data exist on the effectiveness of the ABC (Atrial Fibrillation Better Care) pathway in reducing adverse events in Asian patients with atrial fibrillation (AF) and chronic kidney disease (CKD).

Methods: A post-hoc analysis of the prospective APHRS AF Registry. Patients were divided into CKD (eGFR < 60 ml/min) and non-CKD (eGFR ≥ 60 ml/min) groups.

Chronic kidney disease classification according to different formulas and impact on adverse outcomes in patients with atrial fibrillation: A report from a prospective observational European registry.

Background: Chronic kidney disease (CKD) and atrial fibrillation (AF) often coexist, making accurate renal function estimation crucial, typically through equations calculating estimated glomerular filtration rate (eGFR) or creatinine clearance (CrCl).

Objective: To compare the concordance and predictive performance of different renal function estimation equations in a European cohort of AF patients.

Methods: We analyzed data from AF patients enrolled in a prospective observational European registry.

Gendered social determinants of health and risk of major adverse outcomes in atrial fibrillation.

Introduction: Atrial fibrillation (AF) is associated with an increased risk of adverse outcomes. Clinical risk factors have been identified as predictors of such outcomes, but social determinants of health (SDOH) may also play a role. We evaluated the associations between gendered SDOH (unevenly distributed between sexes) and adverse outcomes in AF.

Association of comorbidity patterns with outcomes and relation with the ABC pathway effectiveness in European patients with atrial fibrillation.

Background: Patients with atrial fibrillation (AF) show increasingly complex comorbidity profiles, with detrimental effects on prognosis.

Objective: The purpose of this study was to explore patterns of comorbidities in patients with AF.

Methods: From a European-wide prospective observational registry of AF patients, we performed a latent class analysis to identify patterns of comorbidities.

Patterns of pharmacological treatment in patients with atrial fibrillation: an analysis from the prospective GLORIA-AF Registry Phase III.

Background: Polypharmacy (i.e., treatment with ≥ 5 drugs) is common in patients with atrial fibrillation (AF) and has been associated with suboptimal management and worse outcomes.

Cardiac vagal control and inflammation are upregulated in exceptional human longevity.

We investigated the interplay of cardiovascular autonomic and inflammatory profiles in persons with extreme longevity (PEL), their direct offsprings (DO), and a group of controls matched for age and sex with the DO. Cardiac autonomic control was assessed through the heart rate variability (HRV) using spectral and symbolic analysis. The plasma concentration and gene expression of interleukin (IL)-10, IL-6, and TNF-α were quantified.

Optimal Medical Therapy for Heart Failure and Integrated Care in Patients With Atrial Fibrillation: A Report From the ESC-EHRA EORP Atrial Fibrillation Long-Term General Registry.

Background: Heart failure (HF) often occurs in patients with atrial fibrillation (AF), with a major impact on prognosis. Few data are available on the effect of integrated treatment strategies to improve prognosis in patients with AF. We aimed to evaluate the association between HF (according to left ventricular ejection fraction [LVEF]), HF optimal medical therapy and adherence to the Atrial Fibrillation Better Care pathway, and major outcomes in patients with AF.

Adverse events in clinically complex elderly patients with atrial fibrillation according to oral anticoagulation status.

Background: Few data are available about the impact of oral anticoagulants (OAC) in patients with Atrial Fibrillation (AF) and clinical complexity (CC).

Methods: We conducted a retrospective study utilising data from the TriNetX network. Based on ICD-10-CM codes entered between 2020 and 2022, AF patients aged ≥75 years on long-term OAC with CC were categorised into two groups based on OAC use in the year before entering the study (maintained vs discontinued).

Peripheral artery disease, antithrombotic treatment and outcomes in European and Asian patients with atrial fibrillation: analysis from two prospective observational registries.

Background: In patients with atrial fibrillation (AF), the impact of peripheral artery disease (PAD) on oral anticoagulant (OAC) therapy use and the risk of outcomes remains unclear.

Objective: To analyse the epidemiology of PAD in a large cohort of European and Asian AF patients, and the impact on treatment patterns and risks of adverse outcomes.

Methods: We analysed AF patients from two large prospective observational registries.

Efficacy of the ABC Pathway for Integrated Care Across Phenotypes of Patients with Atrial Fibrillation: A Latent-Class Analysis Report from the mAFA-II Clinical Trial.

Background: The mAFA-II cluster randomised trial demonstrated the efficacy of a mobile health-technology implemented 'Atrial fibrillation Better Care' (ABC) pathway (mAFA intervention) for integrated care management of patients with AF.

Objective: To evaluate the effect of mAFA intervention across phenotypes of patients with AF.

Design: We conducted a latent-class analysis (LCA) according to eight variables, including age and comorbidities.

Potentially inappropriate prescribing in polymedicated older adults with atrial fibrillation and multimorbidity: a Swedish national register-based cohort study.

Introduction: Current research on potentially inappropriate prescribing (PIP) in polymedicated older adults with atrial fibrillation (AF) and multimorbidity is predominantly focused on PIP of oral anticoagulants (OAC). Our study aimed to assess (i) the overall prevalence of PIP in older multimorbid adults with AF, (ii) potential associated factors of PIP, and (iii) the association of PIP with adverse health outcomes in a nationwide sample of Swedish older adults.

Methods: Swedish national registries were linked to establish a cohort with a 2-year follow-up of older adults (≥65y) who, on 1 January 2017, had a diagnosis of AF and had at least one comorbidity (n = 203,042).

Frailty in Persons with Down Syndrome: Results from the REVIVIS Study.

Objectives: To determine frailty prevalence and identify possible nonclinical factors associated with this condition in community-dwelling individuals with Down syndrome (DS).

Design: Cross-sectional analysis of the registry study REVIVIS, a single-center, prospective study on the geriatric management of persons with DS.

Setting And Participants: Individuals with DS (n = 139) referred to a geriatric clinic.